AIM: To analyze the neutralizing activity of antibodies against E1 region of hepatitis C virus (HCV). Specific polyclonal antibody was raised via immunization of New Zealand rabbits with a synthetic peptide that had been derived from the E1 region of HCV and was shown to be highly conserved among HCV published genotypes. METHODS: Hyper-immune HCV E1 antibodies were incubated over night at 4 degree Celsius with serum samples positive for HCV RNA, with viral loads ranging from 615 to 3.2 million IU/ mL. Treated sera were incubated with HepG2 cells for 90 min. Blocking of viral binding and entry into cells by anti E1 antibody were tested by means of RT-PCR and flow cytometry. RESULTS: Direct immunostaining using FITC conjugated E1 antibody followed by Flow cytometric analysis showed reduced mean fluorescence intensity in samples pre-incubated with E1 antibody compared with untreated samples. Furthermore, 13 out of 18 positive sera (72%) showed complete inhibition of infectivity as detected by RT-PCR. CONCLUSION: In house produced E1 antibody, blocks binding and entry of HCV virion infection to target cells suggesting the involvement of this epitope in virus binding and entry. Isolation of these antibodies that block virus attachment to human cells are useful as therapeutic reagents.
AIM: To analyze the neutralizing activity of antibodies against E1 region of hepatitis C virus (HCV). Specific polyclonal antibody was raised via immunization of New Zealand rabbits with a synthetic peptide that had been derived from the E1 region of HCV and was shown to be highly conserved among HCV published genotypes. METHODS: Hyper-immune HCV E1 antibodies were incubated over night at 4 degree Celsius with serum samples positive for HCV RNA, with viral loads ranging from 615 to 3.2 million IU/ mL. Treated sera were incubated with HepG2 cells for 90 min. Blocking of viral binding and entry into cells by anti E1 antibody were tested by means of RT-PCR and flow cytometry. RESULTS: Direct immunostaining using FITC conjugated E1 antibody followed by Flow cytometric analysis showed reduced mean fluorescence intensity in samples pre-incubated with E1 antibody compared with untreated samples. Furthermore, 13 out of 18 positive sera (72%) showed complete inhibition of infectivity as detected by RT-PCR. CONCLUSION: In house produced E1 antibody, blocks binding and entry of HCV virion infection to target cells suggesting the involvement of this epitope in virus binding and entry. Isolation of these antibodies that block virus attachment to human cells are useful as therapeutic reagents.
Authors: M Enjoji; M Nakamuta; N Kinukawa; R Sugimoto; K Noguchi; S Tsuruta; M Iwao; K Kotoh; H Iwamoto; H Nawata Journal: Med Sci Monit Date: 2000 Sep-Oct
Authors: T F Baumert; S Wellnitz; S Aono; J Satoi; D Herion; J Tilman Gerlach; G R Pape; J Y Lau; J H Hoofnagle; H E Blum; T J Liang Journal: Hepatology Date: 2000-09 Impact factor: 17.425
Authors: Mostafa K el-Awady; Ashraf A Tabll; Yasmine S el-Abd; Mahmoud M Bahgat; Hussein A Shoeb; Samar S Youssef; Noha G Bader el-Din; el-Rashdy M Redwan; Maha el-Demellawy; Moataza H Omran; Wael T el-Garf; Said A Goueli Journal: World J Gastroenterol Date: 2006-08-14 Impact factor: 5.742
Authors: Ahmed Atef Mesalam; Isabelle Desombere; Ali Farhoudi; Freya Van Houtte; Lieven Verhoye; Jonathan Ball; Jean Dubuisson; Steven K H Foung; Arvind H Patel; Mats A A Persson; Geert Leroux-Roels; Philip Meuleman Journal: Virology Date: 2017-11-10 Impact factor: 3.616
Authors: Jean-Christophe Meunier; Rodney S Russell; Vera Goossens; Sofie Priem; Hugo Walter; Erik Depla; Ann Union; Kristina N Faulk; Jens Bukh; Suzanne U Emerson; Robert H Purcell Journal: J Virol Date: 2007-10-31 Impact factor: 5.103
Authors: Mostafa K El-Awady; Ashraf A Tabll; Yasmine S El-Abd; Hassan Yousif; Mohsen Hegab; Mohamed Reda; Reem El Shenawy; Rehab I Moustafa; Nabila Degheidy; Noha G Bader El Din Journal: Virol J Date: 2009-05-27 Impact factor: 4.099